NASDAQ · DCTH
Healthcare · Medical - Devices
$15.41
Down-$0.03 (-0.19%)
Updated Oct 8, 2026, 12:32 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DCTH
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
DCTH closed at $15.41 after 20 trading sessions, down 3.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $15.87 | $15.91 | $15.26 | $15.41 | 244.82K |
| Oct 5, 2026 | $15.18 | $15.97 | $15.0601 | $15.87 | 428K |
| Oct 2, 2026 | $15.57 | $15.60 | $15.06 | $15.13 | 436.64K |
| Oct 1, 2026 | $15.90 | $15.93 | $15.35 | $15.41 | 468.12K |
| Sep 30, 2026 | $15.88 | $16.02 | $15.70 | $15.97 | 300.8K |
| Sep 29, 2026 | $15.80 | $15.94 | $15.66 | $15.85 | 263.7K |
| Sep 28, 2026 | $15.75 | $15.84 | $15.38 | $15.81 | 304.24K |
| Sep 25, 2026 | $16.09 | $16.15 | $15.56 | $15.60 | 262.28K |
| Sep 24, 2026 | $15.91 | $16.10 | $15.52 | $16.08 | 276.46K |
| Sep 23, 2026 | $16.30 | $16.38 | $15.68 | $15.96 | 279.51K |
| Sep 22, 2026 | $16.20 | $16.43 | $16.05 | $16.40 | 368.68K |
| Sep 21, 2026 | $16.25 | $16.25 | $15.87 | $16.11 | 365.51K |
| Sep 18, 2026 | $16.25 | $16.26 | $16.00 | $16.11 | 703.2K |
| Sep 17, 2026 | $16.47 | $16.50 | $16.12 | $16.25 | 437.19K |
| Sep 16, 2026 | $16.16 | $16.485 | $16.06 | $16.22 | 463.17K |
| Sep 15, 2026 | $16.49 | $16.49 | $15.88 | $16.17 | 323.16K |
| Sep 14, 2026 | $15.95 | $16.51 | $15.95 | $16.44 | 503.42K |
| Sep 11, 2026 | $15.99 | $16.00 | $15.73 | $15.91 | 347.06K |
| Sep 10, 2026 | $16.12 | $16.12 | $15.68 | $15.80 | 303.59K |
| Sep 9, 2026 | $16.08 | $16.27 | $15.90 | $15.98 | 384.68K |
The latest Smart Investors Daily articles mentioning DCTH.
Company
Market Activity
Research & News
DCTH research
Company profile and research snapshot.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Feb 26, 2026 | BTIG | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 5, 2025 | Stephens & Co. | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 25, 2026
Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Yahoo · Sep 11, 2026
QUEENSBURY, N.Y., September 11, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026.
Yahoo · Sep 11, 2026
On August 6, Delcath Systems (NASDAQ:DCTH) reported second-quarter results that showed the company selling more of its liver cancer treatment than ever, even as the cost of running the business climbed just as fast. The interventional oncology company posted total revenue of $29.1 million, up from $24.2 million a year earlier, and used the report […]
Yahoo · Sep 8, 2026
VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DCTH.
